Evaluation of antihypertensive efficacy of Losartan + Hydrochlorthiazide versus Telmisartan + Hydrochlorthiazide in patients with stage 1 or stage 2 hypertension: a randomized controlled trial

Manreet Singh Sekhon; Anjleen Kaur; Vijay K. Bajaj; Harcharan Singh; Anita Gupta

doi:10.18203/2319-2003.ijbcp20184318

Authors

Manreet Singh Sekhon Department of Pharmacology, Government Medical College, Patiala, Punjab, India
Anjleen Kaur Department of Pharmacology, Government Medical College, Patiala, Punjab, India
Vijay K. Bajaj Department of Cardiology, Government Medical College, Patiala, Punjab, India
Harcharan Singh Department of Pharmacology, Government Medical College, Patiala, Punjab, India
Anita Gupta Department of Pharmacology, Government Medical College, Patiala, Punjab, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20184318

Keywords:

Cardiovascular disease, Hypertension, Hydrochlorthiazide, Losartan, Uric acid, Telmisartan

Abstract

Background: Cardiovascular disease (CVD) is the most common contributor of morbidity and mortality in underdeveloped and developing countries including the South Asian countries (including India and Pakistan). Amongst the cluster group of CVDs, Hypertension (HTN) represents the most common cardiovascular risk factor. The aim of this trial was to evaluate of antihypertensive efficacy and effect on biochemical parameters of Losartan + Hydrochlorthiazide versus Telmisartan + Hydrochlorthiazide in patients with stage 1 or stage 2 hypertension with a randomized controlled trial.

Methods: This was a prospective, randomized controlled trial of Losartan + Hydrochlorthiazide versus Telmisartan + Hydrochlorthiazide in patients with stage 1 or stage 2 hypertension. The primary endpoint on treatment was analysis of antihypertensive efficacy of these drug combinations. The variables were compared at different time points- baseline, 3 and 6 months.

Results: In the present study, 76 patients were enrolled with 38 patients each allocated to each treatment groups. The effect of Losartan 50mg + Hydrochlorthiazide 12.5mg OD was found to be significant on SBP and DBP in both supine as well as sitting position than Telmisartan 80mg + Hydrochlorthiazide 12.5mg OD group at 3 and 6 months.

Conclusions: The results on anti- hypertensive efficacy was far better in Losartan 50mg + Hydrochlorthiazide 12.5mg OD group than Telmisartan 80mg + Hydrochlorthiazide 12.5mg OD group.

Metrics

Metrics Loading ...

Author Biography

Manreet Singh Sekhon, Department of Pharmacology, Government Medical College, Patiala, Punjab, India

References

Ismail J, Jafar TH, Jafary FH, White F, Faruqui AM, Chaturvedi N. Risk factors for non-fatal myocardial infarction in young South Asian adults. Heart. 2004;90:259-63.

Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vase Health Risk Manag. 2008 February;4(1):23-30.

Bell K, Twiggs J, Olin BR. Hypertension: The Silent Killer: Updated JNC- 8 Guideline Recommendations. Alabama Pharmacy Association; 2015.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC report. JAMA. 2003;289(19):2560-72.

Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit. 2003 Jun;8(3):111-7.

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.

European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.

Kalra S, Kalra B, Agrawal N. Review Combination therapy in hypertension: An update. Diabetology and Metabolic Syndrome. 2010;2:44.

Lacourcière Y, Gil-Extremera B, Mueller O. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract. 2003;57:273-9.

Neutel JM, Littlejohn TW, Chrysant SG, Singh A. Telmisartan Study Group. Telmisartan/ Hydrochlorothiazide in comparison with losartan/ hydrochlorothiazide in managing patients with mild-to- moderate hypertension. Hypertens Res. 2005;28:555-63.

Minami J, Furukata S, Ishimitsu T, Matsuoka H. Comparison of therapies between fixed-dose Telmisartan/ Hydrochlorthiazide and Losartan/ Hydrochlorothiazide in Patients with Mild to Moderate Hypertension. Int Heart J. 2009;50(1):85-93.

Shiga Y, Miura S, Mitsutake R, Norimatsu K, Nagata I, Arimura T, et al. Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension. Journal of the Renin-Angiotensin- Aldosterone System. 2012;13(3):394-400.

Hamada T, Kuwabara M, Watanabe A, Mizuta E, Ohtahara A, Omodani H, et al. A comparative study on the effectiveness of losartan/ hydrochlorothiazide and telmisartan/ hydrochlorothiazide in patients with hypertension. Clin Exp Hypertens. 2014;36(4):251-7.

Eto K, Tsuchihashi T, Abe I, Iida M. Efficacy and safety of combination therapy with losartan and hydrochlorothiazide in elderly hypertension. Nihon Ronen Igakkai Zasshi. [Article in Japanese] Mar 2002;39(2):181 PMID:11974942.